Sisram Med Ltd

Good morning and good afternoon. Thank you everyone for joining us today. Welcome to Cicera Medical four-year 2023 earnings call. This is Qian Li, Vice President of Investor Relations of Cicera Medical. Please note, this event is being recorded. So before we begin, I would like to remind all of our listeners that certain information provided in this call may contain forward-looking statements, and the changes in business, competitive, technological, regulatory, and other factors could cause actual results different materially from the forward-looking statements made today. our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them. except as required by law. This safe harbor statement applies to the core. If you haven't received a copy of the release, please go to the investor relations section of the company's website. Now, I would like to introduce our speakers on the call today. With us on the line today, we have Mr. Liu Yi, CISRAN's chairman, Mr. Leo Dayam, CISREN's Chief Executive Officer, and Mr. Doron Yanai, AMAS CFO. So today, management will begin with an overview of the business development for the core year of 2023. And then following the prepared remarks, we will open the call for the Q&A section. With that, I'd like to turn the call over to Mr. Liu Yi, CISREN's Chairman. Please go ahead.

Thank you, Chen Li. Can you hear me?

Yes, Mr. Liu.